In a randomized controlled study, adding metformin to androgen deprivation therapy for low-tumor-volume metastatic hormone-sensitive prostate cancer significantly delayed development of castration-resistant disease.
Most men with metastatic castration-sensitive prostate cancer (mCSPC) in 2018 did not receive advanced therapies in addition to androgen deprivation therapy (ADT) as first-line treatment for their disease as recommended by clinical practice guidelines, according to real-world data presented at the American Society of Clinical Oncology 2021 virtual annual meeting. This lack of therapeutic intensification…
Androgen deprivation therapy added to radiation therapy (RT) for unfavorable-risk prostate cancer is not associated with an increased risk for cardiovascular mortality compared with RT alone, even among patients with preexisting cardiovascular disease, a study found.
Patients with breast, prostate cancer who are receiving hormonal therapy more likely to develop cardiovascular risk factors
Investigators compared the efficacy, safety, and costs of abiraterone, darolutamide, enzalutamide, and apalutamide in treating nmCRPC.
Findings from a recent study emphasize the importance of neurocognitive assessment in men undergoing ADT, especially in younger patients, according to investigators.
In a propensity score-based study, prostate cryoablation added to androgen deprivation therapy (ADT) improved failure-free survival and survival without castration-resistant disease compared with ADT alone.
In a study, 1 in 4 male veterans with prostate cancer failed to receive a comprehensive assessment of their cardiovascular risk factors.
Real-world data show that a combination of a first-generation anti-androgen drug and androgen deprivation therapy is no better than ADT alone in improving outcomes among men with metastatic castration-sensitive prostate cancer.
The percent decline and actual decline in PSA levels in men with nonmetastatic castration-resistant prostate cancer treated with androgen deprivation therapy and enzalutamide are associated with the risk for death and metastasis, a study found.
